In conclusion, this case report described a patient with CD who developed anti-TNF-alpha agent-associated latent TB infection reactivation in which VDZ was continued as maintenance therapy without inducing TB relapse and summarized the safety profile of VDZ for patients with IBD with active or latent TB infection. Here, TNF is linked to inflammatory bowel disease.